原标题:康方生物-B(09926)免疫双抗龙头,国际化可期 来源:华创证券中国生物药产业正在崛起。随着过去5年中国生物药产业崛起,多个PD-1单抗和biosimilar陆续获批上市。成立8年以来,康方生物已经发展成为国内双抗药物布局最丰富和进展最快的公司之一,拥有一条完全自主研发打造的肿瘤、自身免疫、炎症、代谢疾病等重大疾病的抗体管线,合计12款创新产品处于临床阶段。免疫双抗龙头进入收获期,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.